VWD - Von Willebrand's Disease

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Octapharma
OctapharmaAustria - Vienna
1 program
EqwilateN/A1 trial
Active Trials
NCT04106908Active Not Recruiting38Est. Nov 2026
Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
1 program
The Severe Von Willebrand Disease (sVWD) Patient RegistryN/A1 trial
Active Trials
NCT05437536RecruitingEst. Jan 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Connect BiopharmaThe Severe Von Willebrand Disease (sVWD) Patient Registry
OctapharmaEqwilate

Clinical Trials (2)

Total enrollment: 38 patients across 2 trials

NCT05437536Connect BiopharmaThe Severe Von Willebrand Disease (sVWD) Patient Registry

The Severe Von Willebrand Disease (sVWD) Patient Registry

Start: Dec 2021Est. completion: Jan 2027
N/ARecruiting

Effectiveness and Tolerability of Eqwilate in Real-life Conditions

Start: Nov 2019Est. completion: Nov 202638 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 38 patients
2 companies competing in this space